Navigation Links
URAC Names Medco as a Finalist in First-ever Best Practices in Consumer Empowerment and Protection Awards
Date:11/29/2007

Medco to showcase its winning program at the Best Practices in Consumer

Empowerment and Protection Conference and Exhibit, March 25-26, 2008

WASHINGTON, Nov. 29 /PRNewswire-FirstCall/ -- Today URAC announced that a distinguished panel of judges has selected the finalists for its inaugural Best Practices in Consumer Empowerment and Protection Awards competition. The nation-wide competition attracted entries detailing innovative and proven programs that are enhancing patient safety and giving consumers more control over their health care. Winners represent health plans, pharmacy benefit management organizations, health care management companies and health information technology companies. Medco Health Solutions, Inc. (NYSE: MHS) was among the finalists eligible to receive further distinction as an award winner to be announced March, 2008.

The finalists are invited to present their winning programs at the Best Practices in Consumer Empowerment and Protection Conference and Exhibit, to be held March 25-26, 2008 at the Rosen Shingle Creek Hotel in Orlando. Presentations will showcase working best practices in three categories: consumer decision support, integrated care coordination and patient/consumer safety.

"Our new advanced pharmacy care model, in which Medco's specialist pharmacists are applying their unique expertise to improve care for key health conditions, is already having a profound effect on patients," said Dr. Glen Stettin, Medco's senior vice president & general manager, Clinical & Therapeutic Solutions Group. "In fact the study shows that Medco's Diabetes Resource Center was able to reduce potentially dangerous errors involving syringes and other diabetes supplies, which improved pati
'/>"/>

SOURCE Medco Health Solutions, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
2. Mediware Names Thomas K. Mann Chief Executive Officer
3. Cleveland-based Health Care Tech Company Within3 Names New CEO
4. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
5. Patient Safety Authority Board of Directors Names Infection Advisory Panel
6. Hooper Holmes Names Chris Behling President of Health & Wellness Division
7. MDMA Names New Director of Federal Affairs
8. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
9. Acuo Technologies(R) Names Mike Dolan Vice President of Sales
10. MAKO Surgical Corp. Names Frederic H. Moll, M.D. to Board of Directors
11. Arthur M. Blank Family Foundation Names Susan Bertonaschi Program Officer, Better Beginnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...Ala., Dec. 2 Southern... organization that conducts basic and applied rese...d development, advanced engineering, environmental...has been awarded a subcontract from Black & Ve...e,s Biological Threat Reduction Program (BTRP) in ...
(Date:12/2/2008)...Dec. 2 What is the T Zo...or mouth. Touching your mucous membranes is how m...k. Touching the T Zone is also referred to as dir...e picking, nail biting and many other descriptors.... habit you will help reduce flu and flu-like illne...
(Date:12/2/2008)...SANTA MONICA, Calif., Dec. 2 /PRNewswire-USNewswir...sent a letter today to President-elect Obama urgin...h care affordable and available by allowing any Am...oup warned Obama that a proposal pushed by health ...y private health insurance policies "amounts only ...
(Date:12/2/2008)...e Health Initiative Will Expand to 70 Cities and R... As the first investment...Johnson Foundation (RWJF) has awarded grants of up...y that will serve as leading sites for its most am...y epidemic. , , Healthy Kids, Healthy Comm...
Breaking Medicine News(10 mins):Health News:Southern Research Wins $37 Million Black & Veatch Sub-Contract for Biological Threat Reduction Program 2Health News:Southern Research Wins $37 Million Black & Veatch Sub-Contract for Biological Threat Reduction Program 3Health News:Dr. Will Sawyer and Henry the Hand Champion Handwasher Have Discovered How to PREVENT the Flu and Common Cold!! DO NOT TOUCH the T Zone! 2Health News:Consumer Watchdog to Obama: Open Medicare to All Americans 2Health News:Consumer Watchdog to Obama: Open Medicare to All Americans 3Health News:Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity 2Health News:Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity 3Health News:Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity 4
...isphosphonates are at an increased risk of jaw or ...nates are used to treat cancer-related bone lesio...duced bone density. Several recent studies have f...of intravenous bisphosphonates and osteonecrosis o...
...ople have been bitten and injured by a jackal in B...abies vaccines in the government hospitals to trea... has attacked and injured villagers - including wo...villages under the Manjhagarh block of the distric...
...al progress in curbing the spread of polio with ju...r compared to 676 last year, says WHO. Of the 8...m Uttar Pradesh and 17 from Bihar, it says. 'The...polio in 2007 is 213 compared with 585 for the sam...
...n Pakistan, evoking mixed reactions. <brThei...omething extraordinary. Then the Lahore High Cour...omes as a pleasant surprise is the decision of the... Court to release them on bail and hear their app...
Other Medicine News:Health News:Bisphosphonate Increases the Risk of Jaw Bone Deterioration 2Health News:India Records Substantial Decline in Polio Cases 2Health News:Same Sex Pair Get Relief in Pakistan 2
(Date:12/1/2008)...e study shows the Prox1 gene is a two-way switch t...ells to be reprogrammed so that they lose their id...s , , MEMPHIS, Tenn., Dec. 1 /PRNewswire-US...search Hospital have discovered that a certain dif...entity that it requires the constant expression of...
(Date:12/1/2008)...STGARD, Denmark, December 1 /PRNewswire-FirstCall/...07 with the intent to procure an MVA-based,third...ernment Services,Canada, on behalf of the Canadia...ontract to Bavarian Nordic for the delivery of IMV... to use IMVAMUNE(R) as part of the,country,s bio-...
(Date:12/1/2008)...GO, Dec. 1 Vical Incorpo...t of a $1.0 million milestone payment from Merck &... of a Phase I clinical trial of an investigational...vaccine is based on Vical,s DNA gene delivery tech...riptase (hTERT). hTERT is the subject of separate ...
(Date:11/28/2008)...RLITZ, Germany, November 28 German...eadership in specialized HIV monitoring and,AIDS ...merging countries. In,the year 2008, 2.5 million ...le, robust and highly affordable "CyFlow" system, ...ing with HIV/AIDS. Due to introduction of the,Par...
Breaking Medicine Technology:Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2Fantastic photographs of fluorescent fish 4890 1Old and new therapies combine to tackle atherosclerosis 7697 1Old and new therapies combine to tackle atherosclerosis 7697 2Old and new therapies combine to tackle atherosclerosis 7697 3Water purification down the nanotubes 7695 1Water purification down the nanotubes 7695 2Cadence Pharmaceuticals Updates Omigard 28TM 29 Clinical Timeline 3058 1Cadence Pharmaceuticals Updates Omigard 28TM 29 Clinical Timeline 3058 2Cadence Pharmaceuticals Updates Omigard 28TM 29 Clinical Timeline 3058 3Cadence Pharmaceuticals Updates Omigard 28TM 29 Clinical Timeline 3058 4
...o Company Oncology Programs to be Presented, SOUTH...-FirstCall/ -- Cytokinetics, Incorporated announce...data will be,presented at the 2007 Annual Meeting ...ACR) to be held from April 14- 18, 2007 in,Los Ang...cology,programs at Cytokinetics and will present d...
...--(BUSINESS WIRE)--Apr 9, 2007 -,GlaxoSmithKline (...DLR) today announced data from Study 767905/014 an...rogram for,alvimopan (Entereg/Entrareg(R))., Study...(12,month) study, was designed to evaluate the lon... twice daily in patients taking,opioids for chroni...
Other Medicine Technology:Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 2Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 3Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 4Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 5Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 6Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 7GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 2GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 3GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 4GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 5GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 6GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 7
Wilbrandt-binkhorst irrigating cannula.
Binkhorst, length 18 mm.
Wilbrandt-Binkhorst Cannula have a smooth blunt tip end opening.
Army navy retractor set.
Medicine Products: